Replies to post #389442 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Why do you discuss your speculations on an individual case (anecdotal) as proof of your contention?

It’s hard to imagine you didn’t follow Dr. Prins and Liau’s studies and Dr.Liau’s interview discussions regarding proneural and idh mutation. Since 2011, they have been aware proneural might not respond as well to DCVax-l. https://clincancerres.aacrjournals.org/content/17/6/1603

As shown in Figure 4, patients enrolled on our trial with the proneural gene expression signature had an OS that was indistinguishable from a set of 60 contemporary proneural tumors analyzed from UCLA and 3 other institutions (ref. 21; P = 0.664; Fig. 4A). In contrast to this, patients in our DC vaccine trial with mesenchymal gene expression signatures had a significantly extended survival compared with 82 concurrently collected tumors that were found to have these same gene expression signatures (P = 0.0046; Fig. 4B). — 2011

In interviews, including one with co-interviewee Dr. Cobb, (years ago) Dr. Liau discussed idh mutant as something different than typical GBM, and she’d typically not refer those compassionate cases toward DCVax-l treatment.

[hyperopia]

I'm not aware of anything to suggest that L is less effective with other high grade gliomas. It's just that there hasn't been a formal trial.

I agree that L may be effective with other high-grade gliomas. (the small phase I trial extended survival in some patients) You probably know that UCLA has been running an open label, phase II trial with various adjuvant combinations for malignant gliomas [anaplastic astrocytoma (AA), anaplastic astro-oligodendroglioma (AO)], as well as glioblastoma. I think Dr. Liau and others at UCLA have a pretty good idea who responds to DCVAx, and are looking at adjuvant and checkpoint combinations in an attempt to expand effectiveness in others who are less responsive.

A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen +/- Toll-like Receptor Agonists for the Treatment of Malignant Glioma

https://clinicaltrials.gov/ct2/show/NCT01204684